Friday, July 4, 2025 7/4/2025

A Transporter Platform Technology For Discovery of Drugs to Treat Autoimmune Disease

Award Number: R43GM131477
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2019
PERIOD OF PERFORMANCE END DATE: 02/28/2022

Group Awards By:

View Award Description

A Transporter Platform Technology For Discovery of Drugs to Treat Autoimmune Disease - Project Summary/Abstract ! The longterm goal of Apricity Therapeutics, Inc. (Apricity) is to target pharmacological transporters in the Solute Carrier superfamily (SLC) to treat diseases for which there are no available pharmacological therapies or current therapies are inadequate. SLCs are emerging drug targets because of their numerous associations in human genetic studies with a wide array of common and rare diseases. Autoimmune diseases including inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis and vitiligo are highly associated with polymorphisms in SLC genes, suggesting that SLCs play a major role in the inflammatory and abnormal immune responses that characterize these diseases. The overall goal of this SBIR Phase I proposal is to develop a platform technology for targeting SLC transporters for the treatment of autoimmune diseases with an initial focus on IBD (Crohn's disease and ulcerative colitis). In the United States, IBD is a common autoimmune disease that affects 2-3 million people. The disease involves an immune response and inflammation in the gastrointestinal tract. Genomewide association studies and knockout mice studies have provided evidence that members of several SLC families play a role in the etiology and progression of IBD as well as SLE. In this SBIR Phase I application, we propose to develop reagents that can be used to screen for small molecule inhibitors of transporters in one of the SLC families. Two aims are proposed. In Aim 1, stable cell lines functionally expressing each of the SLC transporters on the plasma membrane will be established and characterized. In Aim 2, fluorescence assays for high-throughput screening will be developed and used (in up to two of the cell lines) to screen a large compound library to discover lead molecules that inhibit uptake of canonical substrates of the transporters. Follow-up studies will be performed to determine the potency and specificity of the compounds in inhibiting each of the transporters. From the proposed research, we expect to discover small molecules with different chemical scaffolds that potently and selectively inhibit these SLC transporters. This innovative project is the first to discover small molecules that target a family of SLC transporters and that can be developed as therapies for autoimmune diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	APRICITY THERAPEUTICS, INC.	953 INDIANA ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Biomedical Research and Research Training	000	1	7/26/2022	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	APRICITY THERAPEUTICS, INC.	953 INDIANA ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Biomedical Research and Research Training	000	1	4/15/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	APRICITY THERAPEUTICS, INC.	953 INDIANA ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Biomedical Research and Research Training	000	1	2/7/2020	NEW	$0
2020	2019	APRICITY THERAPEUTICS, INC.	953 INDIANA ST	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Biomedical Research and Research Training	001	1	7/17/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $223,334 )
2019	2019	APRICITY THERAPEUTICS, INC.	67 JENNINGS LN	ATHERTON	CA	94027	SAN MATEO	USA	Biomedical Research and Research Training	000	1	5/16/2019	NEW	$223,334
														Subtotal = $223,334

Grand Total All Awards = $223,334

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Transporter Platform Technology For Discovery of Drugs to Treat Autoimmune Disease

Award Number: R43GM131477

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2019

PERIOD OF PERFORMANCE END DATE: 02/28/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer